Next-generation diagnostics with eye-tracking

Next-generation diagnostics with eye-tracking

CE_FDA

Our Clinical Importance

Early detection of functional disorders with a dedicated platform and diagnostic device that replaces the manual examination and saves time.

Decentralizing access to screening of brain function by introducing rapid test based on eye tracking.

Rapid, automated screening of brain function supports already understaffed neurological staff by providing them with diagnostic support platform in which the patient does the work and can be operated by anyone.

Generating objective brain function data and results to improve patient lives, health outcome and support research.

Current Tests

Here you can download our new HUB brochure

Our Purpose

Our aim is to offer clinicians and researchers one device that can perform multiple rapid neuro-ophthalmic eye examination tests. Our unique BulbiHUB platform and BulbiCAM currently offers the user multiple tests to screen for glaucoma, age-related macular degeneration (AMD) , nystagmus, cataract and optic neuritis. Ultimately our BulbiCAM will include multiple tests to screen for both ophthalmological and neurological conditions.

Our technology maintains good vision and cognitive health across a lifetime.

Play Video

BulbiCAM - Multiple rapid eye examination tests to screen for ophthalmological and neurological conditions

Play Video

Benefits of Our Technology

Problems We Solve

BulbiCAM

Diagnostic tool in mastering a complete neuro-ophthalmic assessment of the patient

BulbiCAM_3

Our Solution

BulbiHUB Platform

BulbiHUB platform assesses the data measured by BulbiCAM. BulbiHUB is an innovative point-of-care eye platform for the screening of ophthalmological and neurological disorders.

Telemedicine

Assessed data can be shared between and amongst clinical from peripheral locations to one central location, resulting in a clinical workflow that can continue remotely during pandemic outbreaks

AI [Artificial Intelligence]

Algorithms can be developed to detect early stage neuro- ocular dysfunctions and analyze our collected data for research purpose

News

See All Our News

Our Company

Our Timeline

2015
Funding from public funds and private investors for technology development

2016
Technical R&D development on platform & hardware

2017
Company & software CE-certified

2018
Funding from public funds and private investors to complete smaller prototype.

Certified acc to ISO 13485:2016 

2019
Finalist in the DNB Healthcare prize

2020
Bulbitech wins healthcare pitching contest at Oslo Innovation Week

Hardware CE-certified

2021

Bulbitech is FDA registered under number D437315
Awarded € 2 million euro grant from Norwegian Research Council for clinical validation of tests

2022

Semifinalist EIT Health Catapult 2022-2023.
Certified acc to 27001:2013

2023

Completed two validation studies in neurology (Parkinson’s & Ataxia)

Please Subscribe to Our Newsletters

By signing up you agree to our Terms & Privacy.